Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
In a draft guidance published Friday, the US Food and Drug Administration (FDA) says it does not intend to take action against manufacturers who do not affix or imprint a product identifier to each package and homogenous case of products intended to be introduced in a transaction into commerce before 26 November 2018.
"This represents a one year delay in enforcement of the requirement for manufacturers to affix or imprint product identifiers. For the products that manufacturers introduce in a transaction into commerce before November 26, 2018, without a product identifier, FDA also does not intend to take action against manufacturers who do not use a product identifier to verify such product at the package level," the draft says.
As part of the Drug Supply Chain Security Act requirements, manufacturers are required to begin affixing or imprinting a product identifier to each package and homogenous case of a product intended to be introduced in a transaction into commerce no later than 27 November 2017. Repackagers are required to do the same no later than 27 November 2018.
The Act requires that each package and homogenous case of product in the pharmaceutical distribution supply chain include a product identifier in both a human-readable form and on a machine-readable data carrier. The product identifier includes the product’s standardized numerical identifier, lot number and expiration date.
The draft also addresses requirements of the Food Drug & Cosmetic Act (FD&C Act) that, beginning 27 November 2017, manufacturers must:
In addition, the draft addresses requirements for wholesale distributors, dispensers and repackagers related to engaging in transactions involving product with a product identifier and product verification, as well as addressing the requirements for wholesale distributors and repackagers related to saleable returns.
In the future, FDA says it intends to issue additional guidance that will outline FDA’s current thinking on the "grandfathering product" provision of section 582(a)(5)(A) of the FD&C Act regarding products not labeled with a product identifier that are in the pharmaceutical distribution supply chain at the time of the effective date of the requirements of section 582.
Product Identifier Requirements Under the Drug Supply Chain Security Act – Compliance Policy Draft Guidance for Industry
Tags: DSCSA, track and trace, FDA draft guidance